---
title: "NLSP.US (NLSP.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NLSP.US/news.md"
symbol: "NLSP.US"
name: "NLSP.US"
parent: "https://longbridge.com/en/quote/NLSP.US.md"
datetime: "2026-05-21T18:46:35.823Z"
locales:
  - [en](https://longbridge.com/en/quote/NLSP.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NLSP.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NLSP.US/news.md)
---

# NLSP.US (NLSP.US) — Related News

### [Agomab Announces Launch of Initial Public Offering](https://longbridge.com/en/news/274511766.md)
*2026-02-02T12:00:00.000Z*
> AgomAb Therapeutics NV has announced the launch of its initial public offering (IPO) of 12,500,000 American Depositary S

### [NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series](https://longbridge.com/en/news/263510956.md)
*2025-10-30T11:55:19.000Z*
> NLS Pharmaceutics (NLSP) announced the expansion of its DOXA platform with the AEX-6xx series, developed with Aexon Labs

### [Pre-market hot trades in the US stock market: NLS Pharmaceutics up 10.12% in pre-market; Cleveland Cliffs down 9.58% in pre-market](https://longbridge.com/en/news/263461006.md)
*2025-10-30T08:42:52.000Z*
> NLS Pharmaceutics pre-market up 10.12%; Cleveland Cliffs pre-market down 9.58%;

### [](https://longbridge.com/en/news/263352793.md)
*2025-10-29T17:11:17.000Z*
> NLS Pharmaceutics shares are trading lower after the company announced its plans to effect a reverse share split at 1-fo

### [NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger](https://longbridge.com/en/news/263283008.md)
*2025-10-29T11:57:59.000Z*
> NLS Pharmaceutics and Kadimastem have announced the continuation of the ITOL-102 diabetes program following their merger